Cargando…

Diagnosis and management of glutaric aciduria type I – revised recommendations

Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kölker, Stefan, Christensen, Ernst, Leonard, James V., Greenberg, Cheryl R., Boneh, Avihu, Burlina, Alberto B., Burlina, Alessandro P., Dixon, Marjorie, Duran, Marinus, García Cazorla, Angels, Goodman, Stephen I., Koeller, David M., Kyllerman, Mårten, Mühlhausen, Chris, Müller, Edith, Okun, Jürgen G., Wilcken, Bridget, Hoffmann, Georg F., Burgard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109243/
https://www.ncbi.nlm.nih.gov/pubmed/21431622
http://dx.doi.org/10.1007/s10545-011-9289-5
_version_ 1782205405772906496
author Kölker, Stefan
Christensen, Ernst
Leonard, James V.
Greenberg, Cheryl R.
Boneh, Avihu
Burlina, Alberto B.
Burlina, Alessandro P.
Dixon, Marjorie
Duran, Marinus
García Cazorla, Angels
Goodman, Stephen I.
Koeller, David M.
Kyllerman, Mårten
Mühlhausen, Chris
Müller, Edith
Okun, Jürgen G.
Wilcken, Bridget
Hoffmann, Georg F.
Burgard, Peter
author_facet Kölker, Stefan
Christensen, Ernst
Leonard, James V.
Greenberg, Cheryl R.
Boneh, Avihu
Burlina, Alberto B.
Burlina, Alessandro P.
Dixon, Marjorie
Duran, Marinus
García Cazorla, Angels
Goodman, Stephen I.
Koeller, David M.
Kyllerman, Mårten
Mühlhausen, Chris
Müller, Edith
Okun, Jürgen G.
Wilcken, Bridget
Hoffmann, Georg F.
Burgard, Peter
author_sort Kölker, Stefan
collection PubMed
description Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10545-011-9289-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3109243
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-31092432011-07-14 Diagnosis and management of glutaric aciduria type I – revised recommendations Kölker, Stefan Christensen, Ernst Leonard, James V. Greenberg, Cheryl R. Boneh, Avihu Burlina, Alberto B. Burlina, Alessandro P. Dixon, Marjorie Duran, Marinus García Cazorla, Angels Goodman, Stephen I. Koeller, David M. Kyllerman, Mårten Mühlhausen, Chris Müller, Edith Okun, Jürgen G. Wilcken, Bridget Hoffmann, Georg F. Burgard, Peter J Inherit Metab Dis Original Article Glutaric aciduria type I (synonym, glutaric acidemia type I) is a rare organic aciduria. Untreated patients characteristically develop dystonia during infancy resulting in a high morbidity and mortality. The neuropathological correlate is striatal injury which results from encephalopathic crises precipitated by infectious diseases, immunizations and surgery during a finite period of brain development, or develops insidiously without clinically apparent crises. Glutaric aciduria type I is caused by inherited deficiency of glutaryl-CoA dehydrogenase which is involved in the catabolic pathways of L-lysine, L-hydroxylysine and L-tryptophan. This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines). Glutaric aciduria type I is included in the panel of diseases that are identified by expanded newborn screening in some countries. It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. However, initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. Secondary dystonia is often difficult to treat, and the efficacy of available drugs cannot be predicted precisely in individual patients. The major aim of this revision is to re-evaluate the previous diagnostic and therapeutic recommendations for patients with this disease and incorporate new research findings into the guideline. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10545-011-9289-5) contains supplementary material, which is available to authorized users. Springer Netherlands 2011-03-23 2011 /pmc/articles/PMC3109243/ /pubmed/21431622 http://dx.doi.org/10.1007/s10545-011-9289-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Kölker, Stefan
Christensen, Ernst
Leonard, James V.
Greenberg, Cheryl R.
Boneh, Avihu
Burlina, Alberto B.
Burlina, Alessandro P.
Dixon, Marjorie
Duran, Marinus
García Cazorla, Angels
Goodman, Stephen I.
Koeller, David M.
Kyllerman, Mårten
Mühlhausen, Chris
Müller, Edith
Okun, Jürgen G.
Wilcken, Bridget
Hoffmann, Georg F.
Burgard, Peter
Diagnosis and management of glutaric aciduria type I – revised recommendations
title Diagnosis and management of glutaric aciduria type I – revised recommendations
title_full Diagnosis and management of glutaric aciduria type I – revised recommendations
title_fullStr Diagnosis and management of glutaric aciduria type I – revised recommendations
title_full_unstemmed Diagnosis and management of glutaric aciduria type I – revised recommendations
title_short Diagnosis and management of glutaric aciduria type I – revised recommendations
title_sort diagnosis and management of glutaric aciduria type i – revised recommendations
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109243/
https://www.ncbi.nlm.nih.gov/pubmed/21431622
http://dx.doi.org/10.1007/s10545-011-9289-5
work_keys_str_mv AT kolkerstefan diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT christensenernst diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT leonardjamesv diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT greenbergcherylr diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT bonehavihu diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT burlinaalbertob diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT burlinaalessandrop diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT dixonmarjorie diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT duranmarinus diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT garciacazorlaangels diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT goodmanstepheni diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT koellerdavidm diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT kyllermanmarten diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT muhlhausenchris diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT mulleredith diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT okunjurgeng diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT wilckenbridget diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT hoffmanngeorgf diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations
AT burgardpeter diagnosisandmanagementofglutaricaciduriatypeirevisedrecommendations